Related Experiment Videos
Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts
C F Bassøe1, O Bruserud, I F Pryme
1Medical Department B, Haukeland University Hospital, Bergen, Norway.
Leukemia Research
|July 21, 1998
Summary
Ribosome protein factors (GPRE) protect acute myeloid leukemia (AML) blast cells from apoptosis and enhance their phagocytic activity. GPRE also modulates surface molecule expression on AML cells, suggesting a potential therapeutic role.
Area of Science:
- Hematology
- Molecular Biology
- Cell Biology
Background:
- mRNA translation is crucial for cell survival and function.
- Acute myeloid leukemia (AML) is characterized by uncontrolled proliferation of myeloid blasts.
- Understanding factors influencing AML blast cell behavior is vital for developing new therapies.
Purpose of the Study:
- To investigate the effects of ribosome protein factors (GPRE) on acute myeloid leukemia (AML) blast cells.
- To determine if GPRE can prevent apoptosis and enhance phagocytosis in AML blasts.
- To examine the impact of GPRE on AML blast cell surface marker expression.
Main Methods:
- Ribosomes were isolated from MPC-11 cells and GPRE extracted.
- AML blast cells from patients were cultured and treated with GPRE or granulocyte macrophage-colony stimulating factor (GM-CSF).
- Morphological changes, apoptosis markers, phagocytosis, and surface antigen expression (CD11b, CD32, CD35, CD11c) were analyzed.
Main Results:
- GPRE prevented chromatin condensation and nuclear fragmentation in AML blast cells.
- GPRE increased the phagocytic activity of AML blast cells against N. meningitidis.
- GPRE modulated the expression of CD11b, CD32, CD35, and CD11c on AML blast cells.
- GM-CSF potentiated some effects of GPRE, particularly in combination therapy.
Conclusions:
- GPRE exhibits anti-apoptotic effects on AML blast cells.
- GPRE enhances the phagocytic capacity and alters surface molecule expression of AML blasts.
- GPRE's effects may be mediated by ribosomal proteins regulating translation and mRNA distribution, suggesting potential therapeutic applications in AML.